A study on the cost analysis of a rare disease: Multiple myeloma
2012
0 görüntülenme
0 i̇ndirme
Danışman: Doç. Dr. Simten Malhan
Özet (EN)
Multipl Myelom (MM) effects quality of life negatively. But it has a lot of different treatment choices. Altough has low prevelance rate in Turkey. The cost of Multipl Myelom is very high. The aim of the study is to determine cost of Multipl Myelom from the perspectives of Social Security Insurance. In the study, the cost of Multipl Myelom was calculated for one patient as an avereage. At the sometime whole health technologies were included. Treatment stages were first, second and third. All calculations were based on Official Health Bulletin. In addition drug prices were taken by Rx Media Pharma Programme. Consequently one of the Multıpl Myeloma patient averagely was 53.684,56 TL per a year.
Yazar
Dr. Mehmet Ali Alpaslan Şenay
Bu Yayına Nasıl Atıf Yapılır
Mehmet Ali Alpaslan Şenay (Master Thesis). A study on the cost analysis of a rare disease: Multiple myeloma, 2012, Baskent University.
Anahtar Kelimeler
Lisans
Tüm Hakları Saklıdır
Bu eser belirtilen lisans koşulları altında paylaşılmaktadır.
Baskent University tezlerinden daha fazlası
- The relationship of PD-L1/PD-L2 expression and microsatellite instability with tumor variables and prognosis in gastric carcinomas.(2021)
- GaN-based single stage low noise amplifier for X-band applications(2022)
- Aile şirketlerinde marka yönetimi: Ankara'daki aile şirketleri üzerinden bir değerlendirme(2021)
- Mirative markers in Turkish(2021)
- Evaluation of foreign direct investment incentives policies applied in Turkey(2021)
- The impact of entrepreneurship and export volume on economic complexity: A Turkey analysis(2021)
